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Abstract
Background: One essential outcome after breast cancer treatment is recurrence of the disease. Treatment decision is 
based on assessment of prognostic factors of breast cancer recurrence. This study was to investigate the prognostic 
factors for postmastectomy locoregional recurrence (LRR) and survival in those patients.
Methods: 114 patients undergoing mastectomy and adjuvant radiotherapy in Cancer Institute of Tehran University of 
Medical Sciences were retrospectively reviewed between 1996 and 2008. All cases were followed up after initial 
treatment of patients with breast cancer via regular visit (annually) for discovering the LRR. Cumulative recurrence free 
survival (RFS) was determined using the Kaplan-Meier method, with univariate comparisons between groups through 
the log-rank test. The Cox proportional hazards model was used for multivariate analysis.
Result: The median follow up time was 84 months (range 2-140). Twenty-three (20.2%) patients developed LRR. 
Cumulative RFS rate at 2.5 years and 5 years were 86% (95%CI, 81-91) and 82.5% (95%CI, 77-87) respectively. Mean RFS 
was 116.50 ± 4.43 months (range, 107.82 - 125.12 months, 95%CI). At univariate and multivariate analysis, factors had 
not any influence on the LRR.
Conclusion: Despite use of adjuvant therapies during the study, we found a LRR rate after mastectomy of 20.2%. 
Therefore, for patients with LRR without evidence of distant disease, aggressive multimodality therapy is warranted.
Background
Breast cancer is the main cause of death that affects
women worldwide [1]. Women who have been diagnosed
with breast cancer and have completed initial treatments
remain at risk for recurrent cancer [2,3]. Surgery com-
bined with radiotherapy has been the typical treatment
for the breast cancer in order to control loco-regional dis-
ease [4-6]. To avoid recurrence from micrometastasis,
hormone- or chemotherapy adjuvant treatments are
often prescribed.
In the previous reports, the 10-year local recurrence
rates after modified radical mastectomy (MRM) are
around 12% to 27% [7-10]. The locoregional recurrence
(LRR) rate can reach as high as 30% in some studies [11-
13].
Several studies have reported that young age [14,15],
large tumors [16], multiple tumors [17], positive tumor
margins [18], axillary lymph node involvement [16],
extranodal extension [16], extensive ductal carcinoma-in-
situ [19,20] and high nuclear grade [21] are risk factors
for LRR.
Incidence and outcomes data of LRR after mastectomy
are limited by heterogeneous study populations and the
different time period studies. Since it is important to
know the prognostic factors related with LRR and recur-
rence-free survival (RFS) of a population of breast cancer
patients, we retrospectively investigated the recurrence
and survival in patients with breast cancer after MRM.
We mainly analyzed the prognostic factors related with
LRR to identify the subgroup of patients with higher risk
of recurrence for selective treatment (the use of more
effective surgical interventions and/or adjuvant chemo-
or radiotherapy).
Methods
Patients
To evaluate the risk of post-surgery recurrence of breast
cancer, a historical cohort study was designed. The cases
included in this study were selected from the female
patients with breast cancer who had received MRM and
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adjuvant radiotherapy from 1996 to 2008 in Cancer Insti-
tute of Imam Khomeini hospital complex. One of major
teaching hospitals of Tehran University of Medical Sci-
ences in Iran. Unfortunately patients' records of our cen-
ter were incomplete. There were 800 complete records
that one out of 7 was reviewed. A total of 114 patients
were enrolled into this study via systematic random sam-
pling. All cases were followed up (median 84; range 2-140
months) after initial treatment of patients with breast
cancer via regular visit (annually) for discovering the
LRR. In addition to routine clinical examination, disease
assessment included mammography, chest x ray and liver
ultrasonography.
All patients received postoperatively adjuvant chemo-
therapy using CMF regimens (cyclophosphamide, meth-
otrexate, and fluorouracil). Hormonal therapy was given
to Sixty-six (57.9%) of the 114 patients. Hormonal ther-
apy was given to all patients with estrogen receptor (ER)-
positive or progesterone receptor (PR)-positive tumors
by biochemical assay or immunohistochemistry. All
patients received postoperatively adjuvant radiotherapy
which was usually performed intermittently between
courses of chemotherapy. Postmastectomy radiotherapy
to the chest wall was only given to high-risk groups show-
ing locally advanced primary tumor and/or metastatic
axillary lymph nodes. Irradiation of the axilla, paraster-
nal, subclavicular and supraclavicular lymph node
regions was also restricted to these high-risk groups.
Cobalt-60 ray was used. The target sites for radiation
always included supraclavicular/apical axillary regions.
The radiation dose was DT46-50 Gy in conventional frac-
tionations. The 6th edition of the TNM staging system of
the American Joint Committee on Cancer (AJCC) was
used. The histologic grade of the tumors was scored
according to the system of Bloom and Richardson [22].
Patients with distant metastasis detected at the time of
diagnosis and those that their surgical margins were posi-
tive for carcinoma were excluded.
The variables considered in these patients were age,
weight, lymph node involvement, size, stage, grade and
pathology of the tumor using operative and pathology
records. The slides were reviewed by one pathologist.
LRR defined as LRR not predated or followed by distant
metastases within 6 weeks [23]. The RFS was counted
from the beginning date of surgery. The event endpoint
of RFS was the appearance of LRR of tumors in the chest
wall, supraclavicular lymph nodes, axillary lymph nodes,
subclavicular lymph nodes and internal mammary lymph
nodes. All the LRR was confirmed by the pathological
biopsies. This study was approved by the medical ethics
committee of Tehran University of Medical Sciences. We
had no financial support (grants and funds) for study.
Statistical analysis
SPSS 16 software was used for statistical analysis.
Cumulative RFS was determined by using the Kaplan-
Meier method, with univariate comparisons between
groups through the log-rank test. The Cox proportional
hazards model was used for multivariate analysis.
All P-values were tested by two-tailed test, where < 0.05
indicated statistically significant.
Result
The total number of patients included in our study was
114. Median age at surgery was 45 years (range, 26 - 90).
Twenty-three (20.2%) patients developed locoregional
recurrences. The median follow up time was 84 months
(range 2-140).
In the location of 23 cases with LRR, most (91.29%)
w e r e  s e e n  a t  c h e s t  w a l l ,  4 . 3 4 %  a t  i n t e r n a l  m a m m a r y
lymph nodes and 4.34% at axillary lymph nodes (Table 1).
The median time to recur was 44 months (range, 2
months to 30 years).
Patients less than 30 years had the lowest rates of LRR
(4.34%) and those with 30-40 years had the highest rates
(30.43%). Patients with weight of ≤ 50 kg, 90 kg ≤ had the
lowest rates of LRR (4.34%), those with weight of 60-70 kg
had the highest rates (34.78%). Patients with tumors ≤ 2
cm had the lowest rates of LRR (21.7%), those with
tumors 2 to 5 cm had intermediate rates (34.7%), and
those with tumors ≥ 5.0 cm had the highest rates (43.4%).
Table 1: Distribution of loco regional recurrence sites in breast cancer patients.
Site of recurrence Frequency Percentage
Chest wall 21 91.29
Internal mammary 1 4.34
lymph node
Axillary lymph node 1 4.34
Supraclavicular lymph node 0 0
Subclavicular lymph node 0 0
Total 23 100Kheradmand et al. World Journal of Surgical Oncology 2010, 8:30
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Patients with 4-9 lymph nodes had the highest rates of
LRR (52.17%) and those with 10 or more lymph node had
the lowest rates (8.6%). Patients with stage I had the low-
est rates of LRR (4.34%) and those with stage III had the
highest rates (69.56%). Patients with grade 1 had the low-
est rates of LRR (8.6%) and those with grade 2 had the
highest rates (47.82%). Among the recurrent tumors, 21
(91.30%) were invasive ductal carcinoma and 2 (8.7%)
were invasive lobular carcinoma.
Univariate survival analysis
Kaplan-Meier estimates of cumulative RFS rate at 2.5
years (with 95% confidence intervals [CIs]) was 86% (81-
91). At 5 year was 82.5% (77-87). Mean RFS was 116.50 ±
4.43 months (range, 107.82 - 125.12 months, 95%CI).
(Fig. 1) The clinicopathological variables tested in the
univariate analysis are shown in Table 2. Age, weight,
tumor size, nodal status, stage, grade and histology of
tumor were shown no influence on the10-year RFS rate
(p > 0.05).
Overall recurrence rates showed peaks at 5-20 month
(5 and 12%, respectively).
Table 3 shows 10-year RFS rates of patients.
Multivariate survival analysis
According to the results of the multivariate Cox propor-
tional hazards survival analysis, age, weight, tumor size,
nodal status, stage, grade and histology of tumor were not
significant predictors of LRR after MRM (Table 2).
Discussion
In this study, the median follow up time was 7 years and
the LRR rate was 20.2%, a rate similar to those reported
for mastectomy performed in large prospective random-
ized trials. In those trials, local recurrence rate for
patients treated with mastectomy ranged from 2% to 19%.
Table 2: Results of the univariate and multivariate analysis for loco regional cecurrence, according to patient and tumor 
characteristics.
Characteristics Univariate Multivariate
HR 95% CI P value HR 95% CI P value
Age (year) 1.0 0.97-1.03 0.99 0.99 0.96-1.03 0.87
Weight 0.97 0.93-1.02 0.3 0.97 0.92-1.03 0.4
Tumor size
*T1 = ≤ 2 cm
T2 = 2-5 cm 0.49 0.16-1.5 0.21 0.4 0.11-1.43 0.16
T3 = > 5 cm 0.87 0.29-2.55 0.8 0.57 0.15-2.09 0.39
Nodal Status
*N 0 = no 
involvement
N 1-3 0.81 0.21-3.02 0.75 0.32 0.05-1.91 0.21
N 4-9 1.52 0.48-4.79 0.46 0.26 0.02-3.23 0.3
N ≥ 10 0.51 0.11-2.28 0.37 0.09 0.007-1.37 0.08
Stage
*S1
S2 0.95 0.11-7.97 0.96 3.55 0.24-51.72 0.35
S3 1.52 0.2-11.55 0.68 13.18 0.35-485.9 0.16
Grade
*G1
G2 0.98 0.21-4.43 0.98 1.004 0.20-4.96 0.99
G3 1.18 0.25-5.38 0.83 1.14 0.23-5.48 0.87
Histologic type
* Ductal
Lobular 1.21 0.28-5.2 0.78 1.5 0.29-7.53 0.62
*The base groups in Cox analysis are T1, N 0, S1, G1 and Ductal carcinoma.Kheradmand et al. World Journal of Surgical Oncology 2010, 8:30
http://www.wjso.com/content/8/1/30
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The broad range of follow-up time in these studies (6-19
years) may account for the range of recurrence rate [24-
26]. The 15-year LRR rate in 276 patients included in
Danish Breast Cancer Cooperative Group (DBCG) 82b
and 82c trials was found to be 27% [10].
In the present study, most recurrence of breast cancer
occurred within 5-20 months. These results support pre-
vious data from Saphner et al. who identified a peak of
recurrences at 2 years in a large cohort of patients (n =
3,585) enrolled in 7 Eastern Cooperative Oncology Group
studies of postoperative adjuvant therapy [27].
Similar to previous studies [7,28], in the location of
r e c u r r e n c e s ,  c h e s t  w a l l  w a s  m o s t  o f t e n ,  t a k i n g  u p  t o
91.29%.
In this study, RFS rate at 5 - years was 82.5%. Overgaard
et al. reported better 5 - year overall survival (OS) and
disease-free survival (DFS) rates (72% and 61%) [29].
Ragaz et al. reported 5-year-OS and DFS rates of 60% and
47% [30].
Many reports suggested that premenopausal and
younger age at breast cancer diagnosis were unfavorable
prognostic factors for locoregional control and survival
[8,9,31]. In the study of Mansell et al, large tumour size,
high grade, involvement of more than 3 axillary nodes
and the presence of lymhovascular invasion were highly
significant independent predictors of recurrence within
2.5 years (P\0.001) [32]. In the BIG 1-98 trial, significant
predictors of early recurrence in multivariate analysis
also included tumor size and grade and node positivity
[33] and in the study of Komoike et al [34], risk factors of
ipsilateral breast tumor recurrence were younger age,
positive margin status and omission of postoperative irra-
diation.
Additional factors found to be independent predictors
of early recurrence include low ER positivity and human
epidermal growth factor receptor 2 (HER2) overexpres-
sion/amplification [33,35].
Figure 1 Locoregional recurrences free survival of women with breast cancer.Kheradmand et al. World Journal of Surgical Oncology 2010, 8:30
http://www.wjso.com/content/8/1/30
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In this report at univariate and multivariate analysis,
none of factors reached statistical significance to predict
LRR. Patients with tumors ≥ 5.0 cm, 4-9 involved nodes,
stage III, grade 2 and ductal tumor were at increased risk
o f  L R R.  B u t  n o  s t a t i s t i c a l  d i f f e r e n c e  w a s  f o u n d  i n  o u r
group of patients.
About the influence of diet on breast cancer prognosis,
the Women's Intervention Nutrition Study found that a
low-fat diet reduced breast cancer recurrence [36],
whereas the Women's Health Eating and Lifestyle Study
reported that a diet high in vegetables, fruits, and fiber
and low in total fat did not reduce recurrence or mortality
[37]. A growing body of evidence suggests that patients
with higher body mass index (BMI) have been found to
have a higher risk of recurrence [38,39].
As reported in another studies [40,41], Durna et al [42]
found that women who used hormone replacement ther-
apy (HRT) after diagnosis of breast cancer had a signifi-
Table 3: 10-year RFS rates of loco regional recurrence according to patient and tumor characteristics
Characteristics n 10-year RFS (%)
Age (year)
30 ≥ 4 75%
31-40 33 78%
41-50 25 81%
51-60 29 39%
60< 23 73%
Weight
50 ≥ 2 5%
51-60 11 36%
61-70 40 78%
71-80 43 78%
81-90 15 86%
90< 3 66%
Tumor size
T1 = ≤ 2 cm 18 69%
T2 = 2-5 cm 55 85%
T3 = > 5 cm 41 63%
Nodal Status
N 0 20 8%
N 1-3 30 82%
N 4-9 36 60%
N ≥ 10 28 89%
Stage
S1 5 8%
S2 40 85%
S3 69 68%
Grade
G1 10 80%
G2 58 79%
G3 46 68%
Histology
Ductal 105 75%
Lobular 9 77%
*The base groups in Cox analysis are T1, N 0, S1, G1 and Ductal carcinoma.Kheradmand et al. World Journal of Surgical Oncology 2010, 8:30
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cantly lower risk of cancer recurrence or new breast
cancer than women who did not use HRT (RR, 0.62). In
this study, we did not evaluate these factors and recom-
mend evaluating in the future.
Number of all cases in this study was limited and we
reviewed only complete records and we do not know any-
thing about incomplete records. These were limitations
of this study. We hope that more cases accumulation let
better comparison in later studies. Also, our results con-
firmed the previous studies indicated that postoperative
adjuvant radiotherapy is mainly applied for patients with
four or more metastatic axillary lymph nodes and those
with primary tumors at stage T3 or above, who have
higher risk of locoregional recurrence.
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